share_log

What's Going With BioCardia Stock Friday?

What's Going With BioCardia Stock Friday?

生物心脈股票週五有何動向?
Benzinga ·  06/07 22:35

BioCardia, Inc. (NASDAQ:BCDA) shares are trading lower Friday, after initially spiking higher, amid increased volatility in the stock following the company's announcement that it received patent approval.

biocardia公司(納斯達克:BCDA)股價週五下跌,此前曾急劇上漲,公司公佈獲得專利批准後,公司股票出現更大波動。

The Details: On Friday before the market open, BioCardia announced it received approval from the United States Patent Office for its application entitled, "Radial and Transendocardial Delivery Catheter."

詳情:在週五市場開盤前,BioCardia公司宣佈其提交的名爲“放射和透心盤輸送導管”的申請獲得美國專利局批准。

Radial artery delivery uses a wrist blood vessel to deliver biotherapeutic substances and other materials directly to the heart. This method allows patients to leave the hospital soon after with minimal aftercare, reducing hospital costs by eliminating overnight stays.

放射動脈遞送使用手腕血管將生物治療物質和其他物質直接輸送到心臟。該方法允許病人在最少的護理後儘快出院,通過消除夜間住院,減少了醫院成本。

Currently, BioCardia's Helix system is the only known system, with patented designs, that enable this type of treatment. The granted patent claims enhance protection for this approach, thereby adding value to both BioCardia's therapeutic programs and those of our biotherapeutic delivery partners. Additionally, BioCardia's delivery systems are designed to prevent leakage of therapeutic agents by securely engaging heart tissue.

目前,BioCardia公司的Helix系統是唯一已知具有專利設計的系統,能夠實現這種類型的治療。授予的專利權增強了對這種方法的保護,從而爲BioCardia公司的治療方案和我們的生物治療遞送合作伙伴的治療方案增加了價值。此外,BioCardia公司的輸送系統設計用於通過牢固地接觸心臟組織來防止治療劑泄漏。

"Our minimally invasive biotherapeutic delivery platforms enable the successful development of cell and gene-based therapies for the heart," said Dr. Peter Altman, BioCardia CEO.

“我們的微創生物治療輸送平台使得心臟細胞和基因治療的成功發展成爲可能,”BioCardia首席執行官Dr. Peter Altman表示。

Related Link: Expert Ratings For Relay Therapeutics

相關鏈接:Relay therapeutics的專家評級。

BCDA Price Action: At the time of writing, BioCardia stock is 19.6% lower at $3.51, according to data from Benzinga Pro.

BCDA價格行情:據Benzinga Pro的數據顯示,截至撰寫本文時,BioCardia股票下跌了19.6%,報價3.51美元。

Image: 7206876 from Pixabay.

圖片來源:Pixabay的7206876。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論